Given that in mouse models reduced YAP activity negatively interferes with tumour growth[12] and that YAP depletion reduces the metastatic potential of human breast cancer cells[86,96], the development of an antagonist of the YAP-TEAD interaction could have significant therapeutic potential in the treatment of YAP/TAZ-driven cancers. Here, YAP1 is linked to breast carcinoma.